May

Navamedic ASA: Granted European patent for Sippi® base technology

Navamedic ASA: Notice of Annual General Meeting

Navamedic ASA: Q1 2017 results

Oslo, 10 May 2017 - Navamedic ASA (OSE: NAVA), reported revenues of NOK 78.2 million in the first quarter of 2017 (NOK 60.8 million in Q1 2016), representing a growth of 28.6%, in part due to a widened distribution across new European markets under the partnership with TopRidge Pharma.

Navamedic ASA: Invitation to presentation of first quarter results 2017

Navamedic ASA invites you to a presentation of the first quarter 2017 figures.

Navamedic ASA: Enters into partnership agreement with Orexigen Therapeutics for Nordic launch of Mysimba®

Oslo, May 2, 2017 – Navamedic ASA (OSE: NAVA), the Norwegian medtech and pharmaceutical products company, today announced it has entered into a five-year agreement with Orexigen Therapeutics Ireland, Ltd., the subsidiary of the American biopharmaceutical company Orexigen Therapeutics, Inc. (Nasdaq: OREX), for Nordic marketing and distribution of Mysimba®, a prescription pharmaceutical.